Key result
Astragalus polysaccharide improves survival and reduces cardiac edema in a zebrafish model of DCM.
Why the study?
Dilated cardiomyopathy has poor prognosis and genetic causes like tnnt2 mutations, but few specific drugs are available to treat mutation-induced disease.
Does Astragalus polysaccharide improve survival and cardiac function in a tnnt2a mutant zebrafish model of dilated cardiomyopathy?
Does Astragalus polysaccharide improve survival and cardiac function in a tnnt2a mutant zebrafish model of dilated cardiomyopathy?
Astragalus polysaccharide improves survival and attenuates myocardial injury in a zebrafish model of dilated cardiomyopathy by inhibiting apoptosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Astragalus polysaccharide in dilated cardiomyopathy; should not yet inform clinical practice.
BACKGROUND: Dilated cardiomyopathy (DCM) is a severe and irreversible heart disease characterized by dilated ventricles and decreased myocardial function. DCM has a poor prognosis and a very low survival rate, with a 5-year mortality rate ranging from 15 to 50%, and is an important cause of sudden cardiac death and heart failure. Genetic factors play important roles in the pathogenesis of DCM. Mutations in the cardiac troponin T (tnnt2) gene represent an important subset of known pathogenic variants that bind to DCM. However, few specific drugs are currently available to treat DCM caused by these gene mutations. Astragalus polysaccharide (APS), the main active ingredient of Astragalus mongholicus Bunge (Huangqi), is widely used in China to treat cardiovascular diseases, including DCM. This study explored drugs for the treatment of DCM caused by tnnt2a mutation and revealed the protective effect of APS on tnnt2a-mutant dilated cardiomyopathy. METHODS: mutant zebrafish were used as a DCM model for comparison with the APS-treated group. The survival rate and the sinus venosus‒bulbus arteriosus (SV‒BA) distance were used to observe changes in cardiac output. Histopathological changes were observed via hematoxylin and eosin (HE) staining and TUNEL staining. The transcriptomes of the zebrafish in the DCM group and APS-treated group were investigated via RNA-seq. qRT‒PCR detection of apoptosis-related gene expression. Furthermore, APS modulates key muscle fiber-related genes (including ttnb and myom3) and significantly impacts multiple signaling pathways, including Rap1, PI3K-Akt, Jak-STAT, and Wnt signaling. The qRT‒PCR results revealed that APS decreased the expression of bax, caspase-3, and caspase-9 but increased the expression of bcl-2 in DCM zebrafish. CONCLUSIONS: Our findings suggest that APS can improve the survival rate in dilated cardiomyopathy and has a positive protective effect on the myocardium in the tnnt2a mutant zebrafish model of DCM.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied Dilated cardiomyopathy. Astragalus polysaccharide (APS) vs. Untreated tnnt2a-/- mutant zebrafish was evaluated on Survival rate and cardiac function (heart rate, SV-BA distance) (p=<0.01). Astragalus polysaccharide significantly improved survival rate, increased heart rate, and reduced cardiac tissue edema in a tnnt2a mutant zebrafish model of dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: